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1. Introduction 
Schisandra chinesis (S. chinesis) is widely used as one of the 50 fundamental herbs in 
traditional Oriental medicine; the species is a member of the Schisandra genus of shrub, 
which grows commonly in the native forests of Northern China, Korea, Japan and Russia. 
The Schisandra are deciduous climbers that thrive in any type of soil, so long as it is moist, 
shaded, and well-drained (Panossian and Wikman, 2008). The female S. chinesis plant can 
produce the fruit via fertilization with pollen from a male plant (Shilova, 1963). It is 
harvested in most countries, including Korea, by the cutting of half-matured berries 
between August and September. The berries of S. chinesis are called omija (translated as 
“five-flavor fruit”) in Korea, because this fruit has all five of the basic flavors-salty, sweet, 
sour, pungent, and bitter (Gutnikova, 1951; Panossian and Wikman, 2008). Generally, its 
dried fruits have been used for a variety of purposes, including as a therapeutic drug, teas 
and wines. In many countries, it has been used as a therapeutic drug, and is purported to 
have liver-protective and immune-modulatory abilities. A variety of key constituents 
including schizandrin, deoxyschizandrin, gomisin, and pregomisin have been isolated from 
the seeds of the fruit. Additionally, S. chinesis berries have been used in the manufacture of 
several foods. A wine was using the berries of S. chinesis has been produced in China, 
whereas in Korea, the berries are made into a tea. Meanwhile, in Japan, these berries are 
referred to as “gomishin”, and have been used for medicinal purposes, to treat colds and 
sea-sickness. In Russia, dozens of tons of berries are used annually in the commercial 
production of juices, wine, extracts and sweets (Gutnikova, 1951; Agejenko and 
Komisssarenko, 1960). 
A variety of previous pharmacological studies have suggested that S. chinesis may exert 
beneficial biological effects on liver tissue, the central nervous system, the respiratory 
system, the cardiovascular system and the endocrine system (Table 1) (Panossian and 
Wikman, 2008). The major and characteristic components of Schisandraceae berries have been 
previously isolated, and are referred to as lignans. The lignans are categorized into the five 
following classes: dibenzocyclooctadiene lignans (type A), spirobenzofuranoid 
dibenzocyclooctadiene lignans (type B), 4-aryltetralin lignans (type C), 2,3-dimethyl-1,4-
diarylbutane lignans (type D), and 2,5-diaryltetrahydrofuran lignans (type E)(Table 2)(Lu 
and Chen, 2009). Thus far, a total of 43 lignans have been isolated from S. chinesis in various 
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studies; a list is provided in Table 2. Among these lignans, most of the lignans isolated from 
S. chinesis exhibit a dibenzocyclooctadiene lignan (type A) structure, with the exception of 
three lignans: pregomisin, meso-dihydroguaiaretic acid and nordihydroguaiaretic acid. The 
three lignans described in this chapter are of the type A structural group. Additionally, the 
dibenzocyclooctadiene lignans are further divided into two types based on their 
stereostructures-S- and R-biphenyl configuration. Structural elucidation studies have shown 
that the cyclooctene rings of dibenzocyclooctadiene lignans evidence a twist-boat-chair 
(TBC) or twist-boat (TB) conformation (Lu and Chen, 2009). Approximately half of the 
lignans from S. chinesis evidence an S-biphenyl configuration and the other half exhibit an R-
biphenyl configuration. According to the conformation with cyclooctene rings, only four 
lignans exhibited a TB conformation, but the rest of the lignans had the TBC conformation. 
Among the three lignins described in this chapter, only gomisin N exhibits an S-biphenyl 
configuration, whereas tigloylgomisin H and schisandrin A has an R-biphenyl 
configuration.  
 
Body system Regulatory system: stress-
system 
Pharmacological effect: adaptogenic 
effect 
Cardiovascular 
system 
Central and vegetative 
nervous system 
Stimulating effect 
Gastrointestinal 
system 
Endocrine system 
Stress-mimetic and stress-protective 
effect 
Respiratory system Immune system Stress-protective effect 
Table 1. Summary of the pharmacological activities of S. chinensis (Panossian and Wikman, 
2008). 
 
Compounds 
Structure 
type 
Configuration/
conformation 
References 
Gomisin N A S/TBC Ikeya et al., 1978a 
Schizandrin C(wuweizisu C, 
schisandrin C) 
A S/TBC Chen and Shu, 1976 
(-)-Gomisin K1 A S/TBC Ikeya et al., 1980 
Gomisin J A S/TBC Ikeya et al., 1978b 
(-)-Gomisin L2 A S/TBC Ikeya et al., 1982 
(-)-Gomisin L1 A S/TBC Ikeya et al., 1982 
Gomisin S A S/TBC Ikeya et al., 1988 
Epigomisin O A S/TBC 
Ikeya et al., 1991;  
Ikeya et al., 1979 
Tigloylgomisin P A S/TBC 
Ikeya et al., 1990;  
Ikeya et al., 1980 
Angeloylgomisin P A S/TBC 
Ikeya et al., 1990; 
 Ikeya et al., 1980 
Gomisin D A S/TBC Ikeya et al., 1976 
Gomisin E A S/TBC Ikeya et al., 1979 
Gomisin O A S/TBC Ikeya et al., 1979 
6-o-benzoylgomisin O A S/TB Chen et al., 1994 
Angeloylgomisin O A S/TB Ikeya et al., 1982 
www.intechopen.com
 
Therapeutic Effects of Lignans and Blend Isolated from Schisandra chinesis on Hepatic Carcinoma 
 
391 
Angeloyl isogomisin O A S/TB Ikeya et al., 1982 
Benzoyl isogomisian O A S/TB Ikeya et al., 1982 
Schisandrene A S/TBC Choi et al., 2006 
Angeloylgomisin Q A S/TBC Ikeya et al., 1979 
Gomisin F A S/TBC Taguchi and Ikeya, 1977 
Gomisin G A S/TBC Taguchi and Ikeya, 1977 
Schisantherin A(gomisin C, 
wuweizi ester A) 
A S/TBC 
Ikeya et al., 1990;  
Taguchi and Ikeya, 1977 
Schisantherin B(gomisin B, 
wuweizi ester B) 
A S/TBC 
Ikeya et al., 1990; 
 Taguchi and Ikeya, 1977 
Schisantherin D A S/TBC 
Liu et al., 1978;  
Ikeya et al., 1982 
Gomisin R A S/TB Ikeya et al., 1982 
Deoxyschizandrin 
(wuweizisu A, schisandrin A, 
deoxyschisandrin) 
A R/TBC 
Chen and Shu, 1976; 
Yue et al., 1994 
(+)-Gomisin K2 A R/TBC Ikeya et al., 1980 
Schisanhenol [(+)-gomisin K3] A R/TBC 
Ikeya et al., 1980;  
Ikeya et al., 1990 
γ-Schizandrin(γ-schisandrin) A R/TBC Liu et al., 1978 
Schizandrin B(wuweizisu B, 
schisandrin B, (±)- γ-
schizandrin) 
A R/TBC Chen and Shu, 1976 
(±)-Gomisin M1 A R/TBC Ikeya et al., 1982 
(+)-Gomisin M2 A R/TBC Ikeya et al., 1982 
Schizandrin(schisandrol A, 
schisandrin, wuweizi alcohol A)
A R/TBC Chen and Shu, 1976 
Gomisin A(schisandrol B, 
wuweizi alcohol B) 
A R/TBC Taguchi and Ikeya, 1977 
Gomisin H A R/TBC Ikeya et al., 1979 
Angeloylgomisin H A R/TBC Ikeya et al., 1979 
Tigloylgomisin H A R/TBC Ikeya et al., 1979 
Benzoylgomisin H A R/TBC Ikeya et al., 1979 
Gomisin T A R/TBC Ikeya et al., 1988 
Isoschizandrin A R/TBC 
Ikeya et al., 1991; 
 Ikeya et al., 1988 
Pregomisin D / Ikeya et al., 1978 
Meso-dihydroguaiaretic acid D / Ikeya et al., 1979 
Nordihydroguaiaretic acid D / Sakurai et al., 1992 
Table 2. Lignans isolated from the fruits of S. chinensis. A: Dibenzocyclooctadiene lignan; D: 
2,3-dimethyl-1,4-diarylbutane lignan; S or R: the configuration of the biphenyl unit; TBC or 
TB: the conformation of the cyclooctane ring (Lu and Chen, 2009). 
Meanwhile, hepatocellular carcinoma is a primary malignancy of the hepatocytes, and 
generally leads to death within 6-20 months. The disease is the fifth most common cancer in 
men and the eighth most common cancer in women worldwide (Bosch et al., 2004). 
Cirrhosis of any etiology is known to be the major risk factor for hepatocellular carcinoma 
(Adami et al., 2008). Thus far, approximately 80% of patients with newly diagnosed 
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hepatocellular carcinoma have preexisting cirrhosis in the liver organ, caused mainly by 
excessive alcohol use, hepatitis C infection and hepatitis B infection (El-Serang and Mason, 
2000). Additionally, many therapeutic strategies have been attempted to medically treat 
hepatocellular carcinoma, including surgical resection and liver transplantation, although 
the available treatment options depend on the specific characteristics of the tumor (Thomas 
and Zhu, 2005; Bruix and Sherman, 2005).  
There has been some very interesting research conducted to determine whether the lignans 
isolated from S. chinensis may improve and prevent a variety of human diseases, including 
cardiac disease, respiratory disease, immune disease, endocrine disease and neuronal disease. 
However, only a few investigations have been conducted to determine the therapeutic effects 
of lignans isolated from S. chinensis on hepatic carcinoma. Therefore, this chapter describes the 
important results of an experiment using three lignans (gomisin N, tigloylgomisin H (TGH) 
and schisandrin A) and one blend (KY88 Liver-Livo) which may prove valuable in the 
development of a therapeutic drug for the treatment of hepatic carcinoma. 
2. Therapeutic effects of lignans and blend isolated from S. chinensis on 
hepatic carcinoma 
This main section described experimental data regarding the biological effects of three 
lignans and a blend on hepatic carcinoma, and the potential for the use of those lignins as 
therapeutic drugs. 
2.1 Effects of gomisin N 
Gomisin N (Fig. 1) is already well known as a member of the schisandrin B family, and the 
most abundant lignin in the fruit lignins of S. chinensis. Among the various functions of 
gomisin N, its ability to increase antioxidant capacity and protect against mitochondria decay 
was initially identified by a biochemical mechanism study (Ko and Lam, 2002). Additionally, 
gomisin N could induce an increase in heat shock protein, which performed an important 
function when cells and tissues were affected by a variety of stressful stimuli from the external 
environment. Recently, a stereoisomer of gomisin N, (-) schisandrin B, was identified and its 
function in cell protection was investigated. These results demonstrated that schisandrin B and 
(-) schisandrin B were the most potent in enhancing antioxidant protection. Therefore, these 
two lignans may be employed for the protection against and reversal of tissue damage 
induced by environmental hazards, physical exercise, and aging (Chiu et al., 2006). However, 
we found a new function of gomisin N, particularly its effects against hepatic carcinoma. 
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Fig. 1. Chemical structure of gomisin N isolated from S. chinensis. 
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2.1.1 Preparation of gomisin N 
The dried fruits of S. chinensis (2.5 kg) were ground to a fine powder and were successively 
extracted at room temperature with n-hexane, EtOAc, and MeOH. The hexane extract (308 
g) was evaporated under vacuum and chromatographed on a silica gel (40 μm, J.T. Baker, 
NJ, USA) column (70 x 8.0 cm) with a step gradient of 0%, 5%, 10%, 20%, and 30% EtOAc in 
hexane (each 1 L). Of these extracts, Fraction 11IA, one of 5 subfraction originated from 
fraction 11 was further purified by column chromatography on silical gel eluting with 
CHCl3-acetone (19:1) to give a gomisin N (774 mg)(Yim et al., 2009). 
2.1.2 Effects of gomisin N on cell proliferation 
The therapeutic effects of gomisin N on hepatic carcinomas was initially suggested by Yim 
et al. (2009). First, they extracted lignans including gomisin N (Seo et al., 2004), schisandrin 
(Ikeya et al., 1979a), schisandrin C (Seo et al., 2004) and gomisin A (Ikeya et al., 1979b; Park 
et al., 2007) from S. chinensis via n-hexane, EtOAc and MeOH extraction techniques. Their 
structures were analyzed via LC-MS and NMR analysis for identification. Proliferation 
activity was screened for all groups that had received one of the four lignans of varying 
concentrations via an MTT assay to select the lignan with the highest apoptotic effect on 
hepatic carcinoma. For schisandrin C, the MTT assay demonstrated that this lignan induced 
cell proliferation rather than cell death in hepatic carcinoma cells in a concentration range of 
40 μM to 160 μM, whereas the gomisin A-treated group maintained a stable cell population 
(Fig. 2). However, the MTT screening also demonstrated that two lignans, gomisin N and 
schisandrin, significantly induced cell death in relation to other lignans. In the gomisin N-
treated group, cell proliferation in the 40 μM-treated groups was slightly increased 
compared to the vehicle. However, cell proliferation decreased rapidly in a gomisin N 
concentration range from 80 μM to 320 μM (Fig. 2). Schisandrin also induced cell death at 
the higher concentrations, but the cell death ratio was lower than that observed with 
gomisin N (Fig. 2). These results indicated that gomisin N treatment was highly effective in 
inducing the death of hepatic carcinoma cells at higher concentrations, but not at low 
concentrations. Yim et al. selected gomisin N as the candidate lignan for further analysis, 
owing to its anti-proliferation and pro-apoptosis functions. 
 
 
Fig. 2. Anti-proliferative effect of gomisin N, schisandrin, schisandrin C and gomisin A 
isolated from S. chinensis (Yim et al., 2009). 
Additionally, phase-contrast microscope analysis was conducted to determine whether the 
cell death effects observed in the MTT assay were concurrent with the observed cell 
morphological changes. In the 40 μM-treated group, the number and morphology of hepatic 
carcinoma evidenced greater crowding than was observed in the vehicle-treated group. The 
hepatic carcinoma cell line in the 80 μM-treated groups evidenced a pattern similar to that 
observed with the vehicle-treated group. In the 160 μM-treated group, few dead cells were 
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observed in the microscopic images of the hepatic carcinoma cell line. The numbers of these 
cells were increased markedly in the 320 μM-treated groups (Fig. 3). These results 
demonstrated that the results observed on cell morphology analysis under gomisin N-
treated conditions were consistent with the results of an MTT assay under the same 
conditions (Yim et al., 2009). 
 
     
Fig. 3. Microscope images of hepatic carcinoma cell lines after 24 hrs of treatment with 
gomisin N at various concentrations (Yim et al., 2009). 
2.1.3 Effects of gomisin N on apoptosis 
Apoptosis, or programmed cell death, performs a critical role in a variety of physiological 
processes during fetal development and in adult life. Defects in the apoptotic process lead to 
the progress of many diseases involving progressive cell accumulation and cancer in most 
cases. Yim et al. (2009) further investigated the correlation between gomisin N and 
apoptosis. To achieve this, a hepatic carcinoma cell line treated with various concentrations 
of gomisin N were stained with FITC Annexin V, and fluorescence activity was determined 
via flow cytometry. Gomisin N significantly induced the increase in the number of cells 
undergoing apoptosis, from 15% to 98%, in 24 hrs. However, this reaction was induced even 
at low gomisin N concentrations, and this level of induction remained at a constant level up 
to and throughout higher concentrations (Fig. 4). Therefore, these results indicated that 
gomisin N could induce the apoptosis of hepatic carcinoma cell lines in a dose-independent 
manner. Specifically, gomisin N may induce the loss of plasma membrane asymmetry, one 
of the early events in the apoptosis process, for most cells treated at a concentration of 40 
μM. 
 
 
Fig. 4. Identifying apoptotic cells affected with gomisin N treatment. Hepatic carcinoma cells 
were incubated with gomisin N at various concentrations for 24 hrs, and stained with FITC 
Annexin V to detect the apoptotic cells (Yim et al., 2009). 
Additionally, the apoptosis process involves many families of proteins. Among these 
proteins, the Bcl-2 proteins are one of the key molecules in inducing the anti-apoptotic 
process (Apakama et al., 1996). The results of previous studies have shown that this protein 
was overexpressed in many solid tumors, and that it contributes to chemotherapy resistance 
and radiation-induced apoptosis (Apakama et al., 1996; Joensuu et al., 1994). Unlike many 
other known human oncogenes, Bcl-2 exerts its influence by enhancing cell survival rather 
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than by stimulating cell division (Joensuu et al., 1994). Yim et al. (2009) attempted to 
determine whether the expression level of Bcl-2 protein would be affected by gomisin N 
treatment in a hepatic carcinoma cell line. Additionally, Yim et al. (2009) assessed the effects 
of gomisin N treatment on proteins associated with the apoptosis signaling pathway. To 
achieve this, the expression levels of Bcl-2 and Bax proteins were determined in the vehicle-
treated and gomisin N-treated groups via Western blot analysis. The expression level of Bcl-
2 protein did not change in the low concentration range as compared to the vehicle. 
However, the high concentration range-namely the 160 μM and 320 μM-treated groups-
evidenced higher levels of Bcl-2 protein expression than was observed in the low 
concentration range. In the case of Bax, the expression level of this protein was markedly 
increased only in the 320 μM treated group compared to the vehicle and the other 
concentration groups. Furthermore, in order to determine whether the tumor suppressor 
gene would be affected by gomisin N in the hepatic carcinoma cell line, the expression level 
of p53 protein was detected in the vehicle and gomisin N-treated groups. The expression 
level of p53 protein remained unchanged in the four treatment groups and the vehicle (Fig. 
5). These results indicate that gomisin N may simultaneously induce an increase in the 
levels of the proteins associated with the anti-apoptotic and pro-apoptotic processes, but 
does not alter the level of expression of the tumor suppressor protein, p53. 
 
 
Fig. 5. Effects of gomisin N on Bcl-2, Bax and p53 protein expression to investigate the 
mechanism underlying apoptosis (Yim et al., 2009). 
2.2 Effects of KY88 liver-livo (KY88) 
KY88 was one of herbal blends containing Schizandrae fructus (Chow et al., 2001). Thus far, 
three major functions of this drug have been demonstrated; the modulation of the immune 
system, the induction of apoptosis, and the induction of cytokines by lymphocytes and liver 
cancer cells (Chow et al., 2004). However, a thorough determination of the therapeutic 
effects of KY88 against hepatic carcinoma will require further research into its action 
mechanism.  
2.2.1 Preparation of KY88 
KY88 is a blend containing the herbal extract of Schizandrae fructus, Bupleuri radix, Artemisiae 
capillaris, Desmodii herba, Poria sclerotium, Lithospermi radix, Paeoniae radix, Phellodendri cortex, 
Scutellariae radix and Trichosanthis radix. Ten grams of each of all ingredients of above herbs 
were primarily washed and concentrated and purified with the process of extraction. Then, 
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the essence of the herbal extracts -KY88- was assembled. Also, this capsule had been verified 
by SGS Hong Kong Ltd (Socie´te´ Ge´ne´rale de Surveillance) to be free of heavy metals and 
microorganisms. Before the study for inhibition ability, KY88 (50 g) was extracted with three 
times using MeOH. The solid residue obtained from the crude extract was then dissolved in 
dimethyl sulphoxide to a concentration of 92 mg/ml and stored at 4°C until use (Loo et al. 
2007). 
2.2.2 Effects of KY88 on cell proliferation and HBeAg/HBsAg secretion 
Loo et al. (2007) was the first to investigate whether KY88 has an ability to inhibit 
hepatocellular carcinoma cell proliferation and the secretion ability of HBsAg (hepatitis B 
virus surface antigen) and HBeAg (hepatitis B virus core antigen). For this assessment, KY88 
was applied to the HB-8064 hepatocellular carcinoma cell line, and the cell proliferation rate 
and HBsAg/HBeAg secretion were measured on days 1, 3, 5 and 7. The MTT assay showed 
that the treatment of 0.1, 0.5 and 1 mg/ml KY88 for 7 days induced the significant 
suppression of hepatic carcinoma. Additionally, the cell proliferation rate of all KY88-
treated cells was significantly lower than that of the control-treated group (Fig. 6). In 
particular, a remarkable suppression of cell proliferation was detected at three 
concentrations from day 5. Therefore, these data demonstrated that KY88 may potentially 
exert an effect in inhibiting the cellular proliferation of hepatocellular carcinoma. 
 
 
Fig. 6. Dose-dependent inhibition of cell proliferation at three concentrations of KY88 (Loo et 
al., 2007).  
Furthermore, the secretions of HBsAg and HBeAg from the hepatocellular carcinoma cell 
line were dramatically inhibited by KY88 treatment (Fig. 7). The observation of HBsAg and 
HBeAg reflected the cell’s infection with hepatitis B virus and their replication activity (Loo 
et al., 2007). This data indicated that KY88 may potentially have the ability to inhibit the 
proliferation of hepatocellular carcinoma cells, as well as the reduced secretions of HBsAg 
and HBeAg to restrict tumor growth. 
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Fig. 7. Secretion level of HBsAg and HBeAg from hepatocellular carcinoma cell line after 
KY88 treatment (Loo et al., 2007). 
2.2.3 Effects of KY88 on apoptosis and cytokine secretion 
Chow et al. (2004) previously evaluated the effects and action mechanism of KY88 on liver 
cancer cells using methanol extracts of KY88 to develop a novel therapeutic drug for the 
treatment of hepatoma. After methanol extracts of KY88 were applied to a hepatocellular 
carcinoma cell line, the cell proliferation, DNA laddering and cytokine secretion were 
detected in these cells. KY88 induced a significant inhibition of cell proliferation and an 
increase in the DNA ladder pattern, which is a marker that indicates apoptosis in 
hepatocellular carcinoma cells (Fig. 8).  
 
 
Fig. 8. Inhibition effect of KY88 methanol extracts on hepatocellular carcinoma cell (Chow et 
al., 2004). 
Additionally, cytokine ELISA assay results demonstrated that IL-4 and TNF- 
concentrations were increased significantly by KY88 treatment when compared against the 
control group at 24 hrs. However, IL-2, IL-6 and INF- concentrations were maintained at 
constant levels (Fig. 9). Therefore, this data indicates that the methanol extracts of KY88 may 
induce apoptosis via the regulation of IL-4 and TNF- secretion. 
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Fig. 9. Significant change of IL-4 and TNF- level in hepatocellular carcinoma cell after KY88 
treatment (Chow et al., 2004). 
2.3 Effects of schizandrin A 
Schizandrin A is referred to by several other names, including deoxyschizandrin, wuweizisu 
A, and deoxyschisandrin (Lu and Chen, 2009), and is one of the most effective lignins isolated 
from S. chinensis (Fig. 10). Previous studies have also demonstrated that schizandrin A may 
have the hepatoprotective, antioxidative, neurobiological performance-improving and anti-
tumor activities (Deng et al., 2008; Huang et al., 2008). For the first time, the function of 
schizandrin A was found to protect against liver injuries, activate liver regeneration and 
supress liver carcinogenesis (Zheng et al., 1997). Additionally, this lignan was partially used as 
a Ca2+ modulator which induced the synchronization of Ca2+ oscillation via the influx 
inhibition of extracellular Ca2+ and the initiation of action potential (Fu et al., 2008). However, 
only a small amount of research has been conducted regarding the possible inhibitory effects 
of schizandrin A on hepatocellular carcinoma. This chapter also describes recent key results 
regarding the possible anti-liver cancer effects of schizandrin A. 
 
 
Fig. 10. Chemical structure of schizandrin A isolated from S. chinensis. 
2.3.1 Preparation of schizandrin A 
Generally, schizandrin A was prepared with a methods suggested by Chen et al. (1976) and 
Yue et al. (1994). Firstly, S. chinensis Baill (10 kg) was extracted with 50 L of hexane for 1.5 hr 
and the obtained extract was dried under a reduced pressure. The 978.8 g of hexane extract 
were dissolved in 9.8 L of hexane and sequentially extracted two times with 9.8 L of 60% (v/v) 
MeOH. The mixture obtained from above extraction was dried under a reduced pressure and 
finally 112.2 g of a fraction having a high lignan content were obtained. These fraction having a 
high lignan content was subjected to the fractionation high-speed liquid chromatography 
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[column: Kiesel Gel 60 (230 to 400 mesh) supplied by Merk, diameter=10 cm, length=100 cm, 
moving phase: n-hexane/ethyl acetate (7/3), flow rate: 200 ml/min, apparatus: Waters Prep 
LC/System 500A]. Fractions eluted at 63 to 70 minutes in the fractionation high-speed liquid 
chromatography were combined and dried under a reduced pressure. The obtained residue 
(schizandrin A) was recrystallized from methanol to obtain 1.05 g of a colorless prism crystal. 
2.3.2 Effects of schizandrin A and LCC (five schizandrins and crud extract from 
Fructus shizandrae) on human hepatocellular carcinoma  
Huang et al. (2008) evaluated the reversal effects of five schizandrins (schizandrin A, 
schizandrin B, schizandrin C, schizandrol A and schizandrol B) and LCC on multidrug 
resistance (MDR) in several cancer cells, including hepatocellular carcinoma and epidermal 
carcinoma in vitro and in vivo. After treatment with various concentrations of five schizandrins 
and LCC into cancer cell lines, drug sensitivity, apoptosis, doxorubicin (Dox) accumulation 
and protein kinas C (PKC) expression were measured in cancer cell lines. Various levels of 
MDR reversal activity were noted at a 25 M concentration of the five tested compounds. The 
most potent compound found was schizandrin A. The reversal activity of MDR was also 
induced by 25 g/ml of LCC in KBV200, MCF-7/Dox cells, and human hepatic cellular 
carcinoma Bel7402 cells. The flow cytometry analysis results demonstrated that both 
schizandrin A and LCC treatment induced an increase in apoptosis in human hepatocellular 
carcinoma cells. As shown in Fig. 11, the sub-G1 peak, which is one of the characteristics of 
apoptosis, was increased significantly from 1.8% in the Bel7402 cells treated with Dox only to 
10-14% in the schizandrin A + Dox-treated cells or the LCC + Dox-treated cells. Additionally, 
chromatin condensation, another marker of apoptosis, was enhanced in cells treated with 
schizandrin A + Dox or with LCC + Dox. Furthermore, downregulations of PKC and P-
glycoprotein expression were noted in cells treated with schizandrin A + Dox or LCC + Dox 
(Fig. 11). These data showed that schizandrin A and LCC may induce a reversal of MDR in 
cancer cells via the inhibition of P-glycoprotein and PKC expression. 
 
 
Fig. 11. Enhancing effects of schizandrin A and LCC on apoptosis in human hepatocellular 
carcinoma cells. A Control, B Dox 1,250 ng/ml, C Verapamil (VPL) 20 µM, D Dox 1,250 
ng/ml + VPL 20 µM, E Schizandrin A 25 µM, F Dox 1,250 ng/ml + Schizandrin A 25 µM, G 
LCC 25 µg/ml, H Dox 1,250 ng/ml + LCC 25 µg/ml (Huang et al., 2008). 
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2.3.3 Effects of LCC on the tumor growth of mice 
In order to confirm the MDR-reversing effects of LCC and schizandrin A detected in vitro, 
tumor growth was measured in nude mice bearing KBv200 xenografts. Following 10 days of 
vincristine injection, tumor growth was inhibited significantly-by approximately 12%-when 
tumor size was compared to that of the control group (Huang et al., 2008). Furthermore, co-
treatment with LCC and vincristine at 100, 200 and 300 mg/kg BW increased the anti-tumor 
activity induced by vincristine in a dose-dependent manner (Fig. 12). In particular, LCC 300 
mg/kg BW co-treatment for 15 days resulted in dramatic differences-most notably, a 41.9% 
inhibition of tumor size (Huang et al., 2008). These results indicate that LCC has potential 
for use in the development of a therapeutic drug for hepatoma in vivo. 
 
 
Fig. 12. Inhibition effects of LCC on vincristine-induced anti-tumor activity in nude mice 
bearing the KBv200 xenograft (Huang et al., 2008). 
2.4 Effects of TGH 
The structure of TGH (Fig. 13) was firstly assessed by Ikeya et al. (1978a). In Korea, this 
lignin was initially identified via gas chromatography/mass spectrometry (GC/MS) from S. 
chinensis harvested in Muju, Korea (Sohn and Bock, 1989). However, many things remain 
unknown regarding the functions of this lignan. Recently, several important study results 
suggesting a possible function of TGH in cancer therapy have caused an increase in interest 
in the compound.  
 
 
Fig. 13. Chemical structure of TGH isolated from S. chinensis. 
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2.4.1 Preparation of TGH 
In order to prepare TGH, the fruit of S. chinensis (250 g) was firstly extracted three times 
using 500 mL of MeOH with sonication for 1 hr. The dried MeOH extract was collected from 
filtered solution with dryness under reduced pressure. Then, MeOH extract (50 g) was 
suspended in water and sequentially fractionated with n-hexane and CH2Cl2. The purified 
n-hexane fraction (10 g) was subjected to chromatography on an RP-18 column (4.5 x 20 cm, 
5:5 - 9:1 MeOH:water, v/v) to yield fractions 1-8. Furthermore, fraction 4 (650 mg) was 
dissolved in MeOH and subjected to isocratic semi-preparative HPLC using an YMC J-
sphere ODS column (20 x 250 mm, 4 µm; YMC). TGH was separated with MeCN-0.1% TFA 
in H2O (50:50 in 50 min, 10 mL/min, 254 nm) to yield 62.0 mg of compound 4 (93.65%). The 
identity of TGH was confirmed by 1H- and 13C-NMR spectroscopy (Lee et al., 2009). 
2.4.2 Effects of TGH on cell survival 
Lee et al. (2009) initially investigated the anti-cancer functions and action mechanisms of 
nine lignans isolated from the fruit of S. chinensis. Firstly, nine lignans including schisandrol 
A, schisandrol A, TGH, angeloylgomisin H (AGH), schisandrin A, schisandrin B, gomisin J, 
gomisin N and schisandrin C were isolated from S. chinensis and the effects of each lignin on 
the cell survival rate were determined. Among the nine lignans, TGH induced a reduction in 
cell survival at concentrations ranging from 31.3 M to 250.0 M, whereas the AGH samples 
maintained a steady level in terms of cell survival (Fig. 14). During this period, the quinone 
reductase activity was dramatically increased in hepatocarcinoma cells and evidenced a 
high chemoprevention index. Additionally, the mechanism study results demonstrated that 
the expression of genes mediated by the antioxidant response element (ARE), an important 
regulatory region in the promoter of the detoxification enzyme gene which is regulated by 
the nuclear accumulation of Nrf2, was enhanced significantly by TGH. Therefore, all study 
results appear to indicate that TGH may be considered as a potential liver cancer-preventive 
compound that specifically induces increases in antioxidant enzyme expression via the 
formation of the Nrf2-ARE binding complex.  
 
 
Fig. 14. Effects of TGH treatment on the quinone reductase activity and cell survival (Lee et 
al., 2009). 
3. Conclusion 
The development of novel therapeutic drugs for hepatic carcinoma is a very important 
objective in the field of pharmacological research. Among the variety of approaches thus far 
pursued to develop novel drugs, identification and screening of natural compounds from 
www.intechopen.com
 
Recent Advances in Theories and Practice of Chinese Medicine 
 
402 
medical herbs has proven a very effective one-not least, because this method saves a great 
deal of time and cost. Recently, many institutes and companies in advanced countries have 
focused on an approach to novel drugs for hepatic carcinoma via the use of various lignins 
isolated from S. chinensis. This chapter introduces three lignans and one blend which may 
prove valuable in efforts to combat hepatic carcinoma. Gomisin A at high concentration was 
found to significantly induce anti-proliferative and pro-apoptotic effects in hepatic 
carcinoma. Schizandrin A markedly increased vincristine-induced hepatic carcinoma 
apoptosis and anti-tumor activity. Additionally, TGH induced the death of hepatic 
carcinoma cells and inhibited quinone reductase activity. Furthermore, KY88 was a blend 
composed of 10 herbal extracts and effects a dose-dependent inhibition of hepatocellular 
carcinoma cellular proliferation (Table 3). 
Collectively, the results of these studies demonstrated that these lignins and the blend from 
S. chinensis were regarded as an anti-cancer drug candidate capable of inducing apoptosis 
and inhibiting the cell proliferation of hepatocellular carcinoma via a variety of mechanisms.  
 
Compounds Function on hepatocellular carcinoma References 
Gomisin N  Induction of hepatic carcinoma apoptosis 
 Increase of Bcl-2 protein expression 
Yim et al., 2009 
KY88 Dose-dependent inhibition of hepatocellular 
carcinoma proliferation and secretion of HBsAg and 
HBeAg 
Induction of hepatic carcinoma apoptosis and IL-
4/TNF- secretion 
Loo et al., 2007 
 
 
Chow et al., 2004 
 
Schizandrin A Induction of hepatic carcinoma apoptosis and PKC 
down regulation 
Increase of anti-tumor activity induced by vincristine
Huang et al., 2008 
TGH Induction of hepatic carcinoma death and inhibition 
of quinone reductase activity 
Lee et al., 2009 
Table 3. Summary therapeutic function of three lignins and one blend from S. chinensis on 
hepatocellular carcinoma. 
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